Reza Zadno Joins Mobia Medical’s Board of Directors

Mobia Medical Inc. has appointed Reza Zadno, Ph.D., to its board as an independent director and member of the governing body’s Compensation Committee.

“We are pleased to welcome Reza to the Mobia Medical Board of Directors,” Mobia Medical President/CEO Richard Foust said. “He has built and scaled multiple public medical technology companies, and his operational perspective and public company governance experience will be a complementary addition to our board.”

Dr. Zadno brings more than 35 years of medical technology experience, with a track record of building and leading commercial-stage companies through initial public offerings (IPO) and beyond. He was president and CEO and a director at surgical robotics developer PROCEPT BioRobotics from February 2020 to September 2025, leading the company through its 2021 IPO and a period of significant commercial expansion. From September 2016 to November 2020, Dr. Zadno served as president and CEO, and as a board member at Avedro, a public ophthalmology company before its acquisition by Glaukos. Between January 2013 and June 2017, Dr. Zadno served on the Board of Directors and audit committee of Invuity Inc., a public medical device company, before its acquisition by Stryker. From June 2013 through November 2016, he served on the Board of Directors and audit committee of Carbylan Therapeutics, a public biopharmaceutical company, before its merger with KalVista Pharmaceuticals.

“I am excited to join the Mobia Medical Board at this important stage of the company’s commercial expansion,” Dr. Zadno stated. “Vivistim Therapy represents a differentiated technology for stroke survivors. I believe deeply in the company’s mission and the meaningful impact its therapy has on patients’ quality of life. I look forward to working with the board and the management team to support the growth strategy and help bring this innovative technology to more patients around the world.”

Dr. Zadno is currently an operating partner at Jolt Capital, a private equity firm specializing in growth-stage technology investments, and a special advisor to the American Academy of Ophthalmology. He earned a Ph.D. and M.Sc. in mechanical properties of materials (metallurgy) from École Nationale Supérieure de Mines de Paris.

Mobia Medical Inc. is a commercial-stage medical device company attempting to redefine stroke recovery for survivors living with life-altering motor impairments. The company’s Vivistim Paired VNS System is the first and only clinically validated, U.S. Food and Drug Administration-approved implantable solution designed to improve upper limb function in chronic ischemic stroke survivors with moderate to severe upper extremity impairments. Therapy with the Vivistim Paired VNS System combines targeted vagus nerve stimulation with functional movement to promote neuroplasticity and drive meaningful improvements in motor function.